CORC

浏览/检索结果: 共53条,第1-10条 帮助

已选(0)清除 条数/页:   排序方式:
天琴计划简介 期刊论文
中山大学学报(自然科学版)/Acta Scientiarum Naturalium Universitatis Sunyatseni, 2021, 卷号: 60, 期号: 1-2, 页码: 1-19
作者:  罗俊;  艾凌皓;  艾艳丽;  安子聪;  白伟钢
收藏  |  浏览/下载:134/0  |  提交时间:2021/01/18
Vincamine as a GPR40 agonist improves glucose homeostasis in type 2 diabetic mice 期刊论文
JOURNAL OF ENDOCRINOLOGY, 2019, 卷号: 240, 期号: 2, 页码: 195-214
作者:  Du, Te;  Yang, Liu;  Xu, Xu;  Shi, Xiaofan;  Xu, Xin
收藏  |  浏览/下载:102/0  |  提交时间:2019/01/08
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文
JOURNAL OF HEPATOLOGY, 2019, 卷号: 70
作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun
收藏  |  浏览/下载:56/0  |  提交时间:2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载:44/0  |  提交时间:2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载:34/0  |  提交时间:2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载:36/0  |  提交时间:2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载:32/0  |  提交时间:2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载:29/0  |  提交时间:2019/12/05
2017年上海市高等教育教学成果奖《“音乐素质教育”课程体系之改革与实践》 无文献类型
作者:  夏小曹[1];  叶志明[2];  卿扬[3];  阳军[4];  纪晔晔[5]
收藏  |  浏览/下载:5/0  |  提交时间:2019/04/22
Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 期刊论文
HEPATOLOGY, 2018, 卷号: 68
作者:  Wei, Lai;  Xu, Xiaoyun;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Jifang
收藏  |  浏览/下载:21/0  |  提交时间:2019/12/05


©版权所有 ©2017 CSpace - Powered by CSpace